> top > docs > PMC:7309518 > spans > 20549-23994 > annotations

PMC:7309518 / 20549-23994 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T130 1354-1357 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T131 1535-1539 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T132 2207-2218 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T133 2966-2970 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T134 3234-3242 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T48 2966-2970 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T283 14-37 Disease denotes autoimmune neuropathies http://purl.obolibrary.org/obo/MONDO_0000774
T284 50-99 Disease denotes chronic inflammatory demyelinating polyneuropathy http://purl.obolibrary.org/obo/MONDO_0002335|http://purl.obolibrary.org/obo/MONDO_0007691
T286 71-99 Disease denotes demyelinating polyneuropathy http://purl.obolibrary.org/obo/MONDO_0003334
T287 85-99 Disease denotes polyneuropathy http://purl.obolibrary.org/obo/MONDO_0001824
T288 104-131 Disease denotes multifocal motor neuropathy http://purl.obolibrary.org/obo/MONDO_0018979
T289 121-131 Disease denotes neuropathy http://purl.obolibrary.org/obo/MONDO_0005244
T290 173-190 Disease denotes myasthenia gravis http://purl.obolibrary.org/obo/MONDO_0009688
T291 200-223 Disease denotes inflammatory myopathies http://purl.obolibrary.org/obo/MONDO_0007827
T292 445-464 Disease denotes autoimmune disorder http://purl.obolibrary.org/obo/MONDO_0007179
T293 503-511 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T294 766-815 Disease denotes chronic inflammatory demyelinating polyneuropathy http://purl.obolibrary.org/obo/MONDO_0002335|http://purl.obolibrary.org/obo/MONDO_0007691
T296 787-815 Disease denotes demyelinating polyneuropathy http://purl.obolibrary.org/obo/MONDO_0003334
T297 801-815 Disease denotes polyneuropathy http://purl.obolibrary.org/obo/MONDO_0001824
T298 1883-1903 Disease denotes neuromyelitis optica http://purl.obolibrary.org/obo/MONDO_0019100
T299 1972-1980 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T300 1981-1990 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T301 2194-2203 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T302 2353-2374 Disease denotes inflammatory diseases http://purl.obolibrary.org/obo/MONDO_0021166
T303 2465-2473 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T304 2571-2579 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T305 2860-2868 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T306 2880-2915 Disease denotes acute respiratory distress syndrome http://purl.obolibrary.org/obo/MONDO_0006502
T307 2886-2915 Disease denotes respiratory distress syndrome http://purl.obolibrary.org/obo/MONDO_0009971
T308 3102-3110 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T309 3111-3120 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T310 3256-3276 Disease denotes neuromyelitis optica http://purl.obolibrary.org/obo/MONDO_0019100
T311 3299-3316 Disease denotes myasthenia gravis http://purl.obolibrary.org/obo/MONDO_0009688
T312 3353-3356 Disease denotes GBS http://purl.obolibrary.org/obo/MONDO_0016218

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T179 192-194 http://purl.obolibrary.org/obo/CLO_0007874 denotes MS
T180 872-874 http://purl.obolibrary.org/obo/CLO_0007874 denotes MS
T181 1175-1176 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T182 1402-1405 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T183 1533-1539 http://purl.obolibrary.org/obo/CL_0000236 denotes B-cell
T184 1709-1710 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T185 1877-1879 http://purl.obolibrary.org/obo/CLO_0007874 denotes MS
T186 2685-2687 http://purl.obolibrary.org/obo/CLO_0053794 denotes 41
T187 2757-2764 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes viruses
T188 2831-2841 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T189 2923-2925 http://purl.obolibrary.org/obo/CLO_0002131 denotes C5
T190 2966-2970 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T191 2966-2970 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T192 3169-3171 http://purl.obolibrary.org/obo/CLO_0002131 denotes C5
T193 3220-3222 http://purl.obolibrary.org/obo/CLO_0002131 denotes C5

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T95 192-194 Chemical denotes MS http://purl.obolibrary.org/obo/CHEBI_73613
T96 714-722 Chemical denotes steroids http://purl.obolibrary.org/obo/CHEBI_35341
T97 724-737 Chemical denotes mycophenolate http://purl.obolibrary.org/obo/CHEBI_62932
T98 742-754 Chemical denotes azathioprine http://purl.obolibrary.org/obo/CHEBI_2948
T99 872-874 Chemical denotes MS http://purl.obolibrary.org/obo/CHEBI_73613
T100 962-967 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T101 1447-1456 Chemical denotes rituximab http://purl.obolibrary.org/obo/CHEBI_64357
T102 1699-1704 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T103 1854-1859 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T104 1877-1879 Chemical denotes MS http://purl.obolibrary.org/obo/CHEBI_73613
T105 2391-2399 Chemical denotes steroids http://purl.obolibrary.org/obo/CHEBI_35341

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
759 0-8 Species denotes Patients Tax:9606
760 687-695 Species denotes patients Tax:9606
761 858-866 Species denotes patients Tax:9606
762 1086-1094 Species denotes patients Tax:9606
763 1131-1139 Species denotes patients Tax:9606
764 1435-1443 Species denotes patients Tax:9606
765 1727-1735 Species denotes patients Tax:9606
766 1863-1871 Species denotes patients Tax:9606
767 2323-2331 Species denotes patients Tax:9606
768 2451-2459 Species denotes patients Tax:9606
769 2860-2868 Species denotes SARS-CoV Tax:694009
770 2985-2993 Species denotes patients Tax:9606
771 3339-3347 Species denotes patients Tax:9606
772 714-722 Chemical denotes steroids MESH:D013256
773 724-737 Chemical denotes mycophenolate MESH:D009173
774 742-754 Chemical denotes azathioprine MESH:D001379
775 1447-1456 Chemical denotes rituximab MESH:D000069283
776 2391-2399 Chemical denotes steroids MESH:D013256
777 3200-3210 Chemical denotes eculizumab MESH:C481642
778 14-37 Disease denotes autoimmune neuropathies MESH:D001327
779 58-131 Disease denotes inflammatory demyelinating polyneuropathy and multifocal motor neuropathy MESH:D020275
780 173-190 Disease denotes myasthenia gravis MESH:D009157
781 213-223 Disease denotes myopathies MESH:D009135
782 445-464 Disease denotes autoimmune disorder MESH:D001327
783 503-511 Disease denotes COVID-19 MESH:C000657245
784 774-815 Disease denotes inflammatory demyelinating polyneuropathy MESH:D020275
785 1883-1921 Disease denotes neuromyelitis optica spectrum disorder MESH:D009471
786 1972-1980 Disease denotes COVID-19 MESH:C000657245
787 1981-1990 Disease denotes infection MESH:D007239
788 2194-2203 Disease denotes infection MESH:D007239
789 2465-2473 Disease denotes COVID-19 MESH:C000657245
790 2571-2579 Disease denotes COVID-19 MESH:C000657245
791 2880-2915 Disease denotes acute respiratory distress syndrome MESH:D012128
792 2920-2945 Disease denotes C3-C5 complement deposits MESH:C537005
793 2999-3007 Disease denotes COVID-19 MESH:C000657245
794 3102-3110 Disease denotes COVID-19 MESH:C000657245
795 3111-3120 Disease denotes infection MESH:D007239
796 3256-3294 Disease denotes neuromyelitis optica spectrum disorder MESH:D009471
797 3299-3316 Disease denotes myasthenia gravis MESH:D009157

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T12 2089-2113 http://purl.obolibrary.org/obo/GO_0002250 denotes adaptive immune response
T13 2098-2113 http://purl.obolibrary.org/obo/GO_0006955 denotes immune response
T14 2161-2176 http://purl.obolibrary.org/obo/GO_0045087 denotes innate immunity
T15 2731-2753 http://purl.obolibrary.org/obo/GO_0045087 denotes innate immune response
T16 2738-2753 http://purl.obolibrary.org/obo/GO_0006955 denotes immune response

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T75 0-384 Sentence denotes Patients with autoimmune neuropathies, especially chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy, but also with other autoimmunities like myasthenia gravis, MS, and inflammatory myopathies, have been justifiably concerned as to whether their disease status adds an additional risk placing them into an immunosuppressed or immunocompromised category.
T76 385-656 Sentence denotes There is no current evidence that any of the aforementioned autoimmune disorder itself makes them more susceptible to COVID-19, but some immunosuppressive or even immunomodulating therapies they are receiving may have this potential, although there are no validated data.
T77 657-837 Sentence denotes Most autoimmune neuromuscular patients are maintained on steroids, mycophenolate, or azathioprine while most chronic inflammatory demyelinating polyneuropathy receive monthly IVIg.
T78 838-968 Sentence denotes The same applies to patients with MS where it seems safe to start or continue treatment with the standard disease-modifying drugs.
T79 969-1126 Sentence denotes If clinically stable and not lymphopenic, there are no compelling or data-driven reasons to change anything in these patients and disturb clinical stability.
T80 1127-1705 Sentence denotes For patients on monthly IVIg, there may be even a theoretical advantage that IVIg offers additional protection due to natural autoantibodies; if IVIg is not infused as home infusion, switching to self-administered subcutaneous IgG might be an option to diminish exposure, as has been proven effective.37 For patients on rituximab, the infusion intervals can be prolonged to more than 6 months because both B-cell reduction and clinical benefit can persist longer.38 New emerging data provide credence and reassurance regarding these issues, especially on immunomodulating drugs.
T81 1706-1991 Sentence denotes In a large number of patients from Wuhan, published in this issue of the Journal,39 it was shown that altered immunity induced by disease-modifying drugs in patients with MS or neuromyelitis optica spectrum disorder appears insufficient to enhance susceptibility to COVID-19 infection.
T82 1992-2236 Sentence denotes The results are important but not unexpected considering that most of these therapies target the adaptive immune response with little, if any, effect on suppressing the innate immunity that facilitates infection of macrophages and viral spread.
T83 2237-3445 Sentence denotes Similar data from New York City area show that the incidence of hospitalization among patients with immune-mediated inflammatory diseases on therapy with steroids and biologic agents was consistent with that among patients with COVID-19 in the general population, concluding that ongoing use of biologics is not associated with worse COVID-19 outcomes.40 There is also new evidence suggesting possible beneficial effect of anticomplement therapies.41 Complement is an integral component of the innate immune response to viruses and an instigator of proinflammatory responses with evidence that activation of C3 exacerbates SARS-CoV–associated acute respiratory distress syndrome and C3-C5 complement deposits are abundant in the lung biopsies from patients with COVID-19.41 It was proposed that complement inhibition may alleviate the inflammatory complications of COVID-19 infection leading to ongoing trials with anti-C3 and anti-C5 agents.41,42 On this basis, eculizumab, an anti-C5 monoclonal antibody approved for neuromyelitis optica spectrum disorder and myasthenia gravis with some benefits in patients with GBS, may not be withheld, if indicated, as, like IVIg, may theoretically have added benefit.

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T143 71-84 Phenotype denotes demyelinating http://purl.obolibrary.org/obo/HP_0011096
T144 85-99 Phenotype denotes polyneuropathy http://purl.obolibrary.org/obo/HP_0001271
T145 121-131 Phenotype denotes neuropathy http://purl.obolibrary.org/obo/HP_0009830
T146 153-167 Phenotype denotes autoimmunities http://purl.obolibrary.org/obo/HP_0002960
T147 173-183 Phenotype denotes myasthenia http://purl.obolibrary.org/obo/HP_0003473
T148 200-223 Phenotype denotes inflammatory myopathies http://purl.obolibrary.org/obo/HP_0009071
T149 445-464 Phenotype denotes autoimmune disorder http://purl.obolibrary.org/obo/HP_0002960
T150 787-800 Phenotype denotes demyelinating http://purl.obolibrary.org/obo/HP_0011096
T151 801-815 Phenotype denotes polyneuropathy http://purl.obolibrary.org/obo/HP_0001271
T152 2886-2906 Phenotype denotes respiratory distress http://purl.obolibrary.org/obo/HP_0002098
T153 3299-3309 Phenotype denotes myasthenia http://purl.obolibrary.org/obo/HP_0003473

2_test

Id Subject Object Predicate Lexical cue
32518172-29122523-75850535 1428-1430 29122523 denotes 37
32518172-18519875-75850536 1590-1592 18519875 denotes 38
32518172-32503092-75850537 1787-1789 32503092 denotes 39